Gene therapy study produces promising results for hemophilia B patients

A fraction of patients with a common form of the bleeding disorder hemophilia develop anallergic reaction to the blood-clotting treatment they need to keep them alive. But using gene therapy, University of Florida researchers were able to reverse this reaction and provide long-lasting treatment for the disease in an animal model, according to findings published today in the journal *EMBO Molecular Medicine*.

If successful in humans, gene therapy could not only provide much-needed therapy for patients with hemophilia B, but also spare them from costly and difficult treatment regimens, said Roland Herzog, Ph.D., a professor of pediatrics in the UF College of Medicine and a senior author on the paper.

Read the full, original story here: Gene therapy study produces promising results for hemophilia B patients